Your browser doesn't support javascript.
loading
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf, D J; Aragón, I M; Annala, M; Lozano, R; Taavitsainen, S; Lorente, D; Finch, D L; Romero-Laorden, N; Vergidis, J; Cendón, Y; Oja, C; Pacheco, M I; Zulfiqar, M; Gleave, M E; Wyatt, A W; Olmos, D; Chi, K N; Castro, E.
Afiliação
  • Khalaf DJ; BC Cancer Vancouver, Vancouver, BC, Canada.
  • Aragón IM; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain.
  • Annala M; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Lozano R; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain.
  • Taavitsainen S; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Lorente D; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Hospital General Universitari de Castelló, Castellon, Spain.
  • Finch DL; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; BC Cancer Kelowna, Kelowna, BC, Canada.
  • Romero-Laorden N; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Vergidis J; BC Cancer Victoria, Victoria, BC, Canada.
  • Cendón Y; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Oja C; BC Cancer Surrey, Surrey, BC, Canada.
  • Pacheco MI; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Zulfiqar M; BC Cancer Abbotsford, Abbotsford, BC, Canada.
  • Gleave ME; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Wyatt AW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Olmos D; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain.
  • Chi KN; BC Cancer Vancouver, Vancouver, BC, Canada; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Castro E; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain; Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regi
Ann Oncol ; 31(9): 1186-1197, 2020 09.
Article em En | MEDLINE | ID: mdl-32574722
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias de Próstata Resistentes à Castração / Antagonistas de Androgênios Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias de Próstata Resistentes à Castração / Antagonistas de Androgênios Idioma: En Ano de publicação: 2020 Tipo de documento: Article